COVID-19 & Geschäftschancen im Medizinbereich in Zentralasien€¦ · • 10 of the 70 Kazakh...
Transcript of COVID-19 & Geschäftschancen im Medizinbereich in Zentralasien€¦ · • 10 of the 70 Kazakh...
WEBINAR | 23.06.2020
COVID-19 & Geschäftschancen
im Medizinbereich in
Zentralasien
Mit freundlicher Unterstützung von:
WEBINAR
AGENDA
• 13.00 – 13.10
Introduction & Overview
Lisa Kronreif, österr. Wirtschaftsdelegierte Stv.
AußenwirtschaftsCenter Almaty
• 13.10 – 13.25
Hospitals Programme in Kazakhstan
Business and consultancy opportunities
Svetlana Radchenko, Associate Director, Senior Banker,
Infrastructure – Eurasia
European Bank for Reconstruction & Development (EBRD)
• 13.25 – 13.35
New Reality – Transformation of Business and Opportunities
Nickolay Demidov, General Manager, IQVIA Russia/CIS
• 13.35 – 13.45
Panel Discussion with Austrian healthcare companies
Arminas Macevicius, Head of Asia-Caucasus Cluster, Takeda
Ralph Lugbauer, CEO, Askin
• 10.45 – 11.00
Q & A Session
WHAT‘S THE PLAN?
Entry and travel regulations
Regulations for freight transport of health products Support measures by the state for health industry Updated COVID-19 information
Kazakhstan From 20.06. flights to
and from Turkey,
China, South Korea,
Thailand, Georgia
and Japan
• Only drivers with a negative COVID test can enter.
Express tests at the border within 6-8 hrs.
• “Green corridor” for deliveries of food and
pharmaceuticals. Special regulation for health
products at border crossings that are otherwise
closed (Kolzhat (Almaty region), Bachty and
Maikaptschagai (Eastern Kazakhstan region).
• EEU export ban until 30.09. for disinfection products,
protective equipment (masks, respiratory masks, gloves,
disposable protective clothing and wipes, protective
glasses, etc.), wound closure materials and bandages,
propyl alcohol and isopropyl alcohol• Modernization plan of the health sector
LINK
Kyrgyzstan No international
flights
• Road transport: driver has to pass express test,
truck has to be disinfected regardless of type of
cargo
• Freight transport via air is allowed to land
• State improves healthcare facilities, buys express tests
and self-protection items via humanitarian aid
• Kyrgyzstan arranged a laboratory for PCR test in Bishkek
LINK
Tajikistan From 01.07. flights to
and from VAE and Uzbekistan
• Since 09.06.: foreign drivers and transports can
enter Tajikistan for 5 days with negative COVID test
• In case driver does not have negative COVID test:
express test at border and driver is quarantined at
border until test results available. If test is
negative: driver can travel to final destination
• 01.07.-01.09. exemption from customs duties for imports
of materials for the production of disinfectants,
medicine and protective clothing, equipment for medical
laboratories, testing equipment; exemption from
taxation also for medical institutions related to patient
treatment of COVID-19
• regulation of prices for medicines, medical supplies,
masks, antiseptics etc.
• soft loans to companies producing medical products
LINK
Uzbekistan From 01.07. flights to
and from Russia and Tajikistan
• Since 30.04.: mandatory COVID test for truck
drivers in special parking spots. Drivers required to
wear protective overalls, gloves, masks during their
stay in Uzbekistan. Foreign drivers obliged to leave
country within 10 days.
• At borders, truck drivers receive maps indicating
where they are allowed to stop.
• Reimbursement of 50% of transport costs for Uzbek
export companies for exports of certain medicines.
• Export ban of the following items for the production of
medical products from 01.05. until 31.12.2020: SMS non-
woven fabric, spunbond nonwoven fabric, non-woven fabric meltblown
LINK
* Turkmenistan – Officially there are no COVID-19 cases in the country.
GET OUR
PUBLICATION!
BRANCHENPROFIL MEDIZINTECHNIK,
LABORBEDARF & PHARMAZEUTIK
HEALTH
EXPENDITURE
GDP SHARE OF HEALTH EXPENDITURE IN KAZAKHSTAN
10,4% 10,4% 10,3%
8,9% 8,8% 8,8%
3,3% 3,5%3,9%
2016 2017 2018
Austria OECD Ø Kazakhstan
Source: OECD; Statistics committee of the Republic of Kazakhstan
HOSPITAL BEDS
HOSPITAL BEDS PER THOUSAND INHABITANTS 2018
Source: OECD; Statistics committee of the Republic of Kazakhstan
7,6
5,0 6,7
Austria OECD Ø Kazakhstan
IMPORTS
IMPORT PHARMACEUTICALS & MEDICAL DEVICES
IN MLN. USD
Source: OECD; Statistics committee of the Republic of Kazakhstan
1222
9611093
1177
185 144201 197
2015 2016 2017 2018
Pharmaceuticals CTN 30 Medical Equipment CTN 9018
MEDTECH
COMPETITION
• State is the largest purchaser
• Imports of surgical devices
2016: 144 mln. USD (AT: 0,9 mln. USD)
2017: 201 mln. USD (AT: 1,8 mln. USD)
2018: 197 mln. USD (AT: 1,3 mln. USD)
2019: 222 mln. USD (AT: 0,7 mln. USD)
• High dependence on imports
Import shares of main supplier countries 2019:
Germany: 19%
China: 15%
USA: 13%
Japan: 9%
Russia: 8,5%
South Korea: 8%
-----
Austria: 0,3%
MEDTECH COMPETITION SITUATION
HIGH DEPENDENCE ON IMPORTS
PHARMA
COMPETITION
• 10 of the 70 Kazakh pharmaceutical
manufacturers produce 90% of the meds
"Made in Kazakhstan“
• High dependence on imports
• Local production covers 14% of own needs
(mainly production of generics)
• Annual needs: approx. 1 bln. USD
• Mainly importing from Germany, France, Russia
• Purchase of local products shall be increased from
currently 30 to 73 bln. Tenge by 2024
(approx. 66 mln. EUR to 160 mln. EUR)
PHARMA COMPETITION SITUATION
HIGH DEPENDENCE ON IMPORTS
TRENDS I
• In recent years: fundamental improvements in
healthcare
• Healthcare development program 2020-2025
• COVID-19 pandemic requires modernization: from
inpatient to outpatient treatment
• Early detection of diseases
• Prevention
• Pediatric modernization
• Training and advanced education of medical
personnel
TRENDS IN THE HEALTH SECTOR
TRENDS II
• Promotion of local production of medical
equipment
• Incentives for foreign investors active in high-
tech medical technology
• Medical tourism
Incoming: artificial fertilization, dentistry
Outgoing: cardio- and neuro-surgery, organ
transplantation, oncology
• State finances complicated treatments abroad
(tumors, transplants, etc.)
TRENDS IN THE HEALTH SECTOR
OPPORTUNITIES
& CHANCES
• Digitalization (e-learning, robotics, etc.)
• Big Data and Artificial Intelligence
• 3D-printing
• Predicting patient needs
• Improving research and drug/therapy development
• Hospital infrastructure/PPP projects
• Hospital consulting/management
OPPORTUNITIES FOR AUSTRIAN COMPANIES
EVENTS
PARTICIPATE IN OUR NEXT EVENTS!
YOU CAN FIND ALL OUR EVENTS HERE:
wko.at/aussenwirtschaft/veranstaltungsprogramm
• RECORD-TRADE MISSION UZBEKISTAN
24. – 28. February 2020 | TASHKENT & SAMARKAND | UZBEKISTAN
• WEBINAR VIRTUELLER EXPORTTAG
WACHSTUMSREGION ZENTRALASIEN: CHANCEN & POTENTIALE
30. June 2020
• GROUP EXHIBITION MINING & METALS CENTRAL ASIA 2020
16. – 18. September 2020 | ALMATY | KAZAKHSTAN
LINK TO EVENT
• AUSTRIA CONNECT GUS 2020
16. – 18. September 2020 | MOSCOW | RUSSIA
LINK TO EVENT
• TRADE MISSION TAJIKISTAN & KYRGYZSTAN
19. – 23. October 2020 | DUSHANBE & BISHKEK
LINK TO EVENT
• WIRTSCHAFTSDELEGIERTEN-SPRECHTAG AFRIKA, NAHOST, GUS, TÜRKEI, IRAN 2020
09. – 20. November 2020 | ÖSTERREICH
LINK TO EVENT
• TRADE MISSION TURKMENISTAN
30. November – 04. December 2020 | ASHGABAT | TURKMENISTAN
LINK TO EVENT
14
SILK ROAD BIZ
AWARD 2021
ERZÄHLEN SIE UNS
VON IHREN ERFOLGSGESCHICHTEN!
Bewerben Sie sich für den Silk Road Biz Award 2021 des
AußenwirtschaftsCenter Almaty, mit dem wir
Spitzenleistungen österreichischer Unternehmen in
Zentralasien prämieren.
Ein formloses E-Mail an [email protected] ist ausreichend.
Die Bewerbung läuft noch bis 25. Dezember 2020.
SILK ROAD BIZ AWARD 2020 | GEWINNER
• BERTSCHlaska
• Herz Armaturen
• Starlinger & Co
Hospitals Programme in Kazakhstan
Business and Consultancy Opportunities
Svetlana Radchenko
Associate Director, Senior Banker, Infrastructure – Eurasia
European Bank for Reconstruction and Development (EBRD)
EBRD
Hospitals Programme in Kazakhstan – business and consultancy opportunitiesJune 2020
Content
Sustainable Infrastructure Group 18
1. Business Opportunities in Hospitals Programme
2. PPP Projects supported by the EBRD
3. Consultancy Opportunities
4. PPP Regime & Legislation Issues
5. Contacts
19
Business Opportunities
20
19 new hospitals, total project cost 1 137 billion Tenge, including:
• 4 projects under quasi-PPP procurement mechanism (“direct selection” – not financed by IFIs)
• 11 PPPs projects, 6 of which are being prepared with EBRD
• 1 sovereign guaranteed Design-Build-Operate-Maintain contract
• Procurement modes for other projects are being contemplated
Business Opportunities in KZ – Hospitals
21
• Government plans to procure up to
19 general hospitals in 2020-2025.
• Preliminary estimate of design and
CapEx is around $4.3 billion.
• Facility management will be a
working model for private sector
involvement.
• EBRD is supporting the Ministry of
Healthcare on preparation of 7
hospital projects worth $1.6 billion.
Hospital in Kyzylorda to be procured
via Design-Build-Operate&Maintain
contract, while other via PPP.
Location Beds
Almaty (PPP) 300
Kyzylorda (DBOM) 500
Kokshetau (PPP) 630
Kostanai (PPP) 500
Pavlodar (PPP) 500
Taraz (PPP) 500
Atyrau (PPP) 500
Business Opportunities in KZ – Hospitals
Location and preliminary design
Historica
l center
Nauryzbay
district
Key details
Construction and facility management of
multidisciplinary hospital in Almaty city (population
around 2 million) for 300 beds (medical services will
be provided by National Medical University);
Grantor: Ministry of Health;
Project: USD 170 million (including contingencies,
insurance, SPV, FIDIC advisor, excluding VAT);
Contract type: DBFM;
Term: 25 years;
Availability payment for facility management;
Revenues for non-clinical commercial services.
Current status
Consultancy support for project preparation is
provided by KPPF, local publicly owned PPP advisor
and IPPF;
Tender documentation was prepared by KPPF, and
was revised by international consultants hired under
IPPF management;
Tender documentation is on Government approvals
stage.
Tender announcement is expected in Q42020.
Almaty Hospital PPP a.k.a AsfendiyarovaHospital
22
Kyzylorda general hospital
Key details
Construction and facility management of multidisciplinary hospital in Kyzylorda city (population around 240k) for 500 beds
(medical services will be provided by the Ministry of Health);
Application of new hospital construction standards which are being developed for Kazakhstan;
Contract type: Design-Build-Operate-Maintain;
Contract term: 10-15 years;
Separate payments to contractor for construction and facility management;
Financing of construction: EBRD loan to National Medical Operator under the sovereign guarantee;
Financing of facility management: subsidy from the Government of Kazakhstan;
Status
EBRD is hiring healthcare planner to develop functional specifications for Kyzylorda and 5 other hospitals.
Consultant for the development of the Feasibility study, outline design and legal structure to be hired in August 2020.
Consultancy support for project preparation is funder by Kazakhstan TC fund;
Tender for DBOM contract is expected in 2H2021.
23
EBRD support to bidders in PPP projects
24
EBRD support to bidders:
• EBRD can issue a general letter of interest to be included in the tender
• The Bank can have a pre-bidding dialogue with players
• Instruments offered: joint equity investment and/or capex loan
• Indicative terms: tenor, security
• Until tender award, EBRD cannot commit to exclusivity with anyone (‘open support’)
• Identical dialogue possible with all bidders
• Different teams established to guarantee Chinese walls
• After tender award, EBRD negotiates detailed terms and conditions with the preferred bidder subject to detailed due diligence of the project
25 June, 2020
Financing by EBRD in tenge
EBRD can provide financing of projects in multiple currencies, including EUR, USD, RUB,
KZT and other
KZT funding with fixed interest rate can be provided for the term of up to [4] years.
Long-term financing in KZT is possible based on floating rate basis:
Floating rate base – Consumer Price Index (CPI)
Total interest rate = CPI + EBRD treasury margin + credit margin
EBRD treasury margin depends on money market and funding availability from
NBR, pension funds. Typically [0.5-2%]
Credit margin depends on creditworthiness of the borrowers
26
Consultancy Opportunities
Consultancy Opportunities in KZ – Hospitals
27
• Healthcare planning for 6 regional hospitals
Cost up to €1m. Procurement is ongoing
• Preparation of a Feasibility study for Kyzylorda hospital
Cost up to €1m. Procurement is ongoing
• PPP Transaction Advisory for 5 Hospitals.
Cost tbd. Procurement will start in 2H2020.
• Project management and construction supervision for Kyzylorda
hospital
Cost of €5-6m. Procurement will start in 2021
28
PPP Regime & Legislation Issues
Option 1: Concession Law Option 2: PPP Law
• The Concession Law (with only one PPP model
available – BTO) was developed for major
infrastructure projects and, therefore, has quite
detailed approval requirements for each project.
• Only contractual PPP – no JVs with private investors.
Concession agreement may have only 2 parties.
• Strict budgeting process - all obligations under
concessions should be approved by the Ministry of
Finance.
• Direct agreement – available for the “special
importance” projects.
• Only “special importance” projects can benefit from
an international arbitration.
• Use of SPVs is stipulated in the Law.
• The Law was created with intention to structure
small-scale infrastructure projects. Approval process
is more flexible than in Concession Law.
• 3-party agreement and JVs with private partners are
envisaged. Private Financial Initiative is allowed.
• Several models of PPP are envisaged– see Article 7
of the Law.
• Direct agreement – available for the “special
importance” projects.
• Only “special importance” projects can benefit from
an international arbitration.
• Use of SPV is not stipulated in the Law.
Since the existence of two laws is not practical the Government of KZ
discusses the merger option (single law) or strict separation of two
laws (PPP law – only for O&M contracts).
29
PPP legislation in Kazakhstan: two laws - two sets of regulation
Issue Description
Lenders direct agreement The concept of “direct agreement” is available only for PPP projects of “special importance”.
The criteria for projects of “special importance” are rather restrictive.
International arbitrationOnly “projects of special importance” can benefit from an international arbitration clause in a
PPP / concession agreement.
Budgeting of termination
payments
The budget legislation does not provide for a clear procedure for budgeting long-term
obligations under PPP / concession agreements or a procedure for budgeting termination
payments.
PPP budget limits PPP/concession budget limits set for regional Akimats are restrictive (1-2 projects maximum).
Tender process
The tender process for PPPs/concessions is not in line with best international practice: e.g.
requirement to submit technical pre-feasibility study, use of only financial criteria for PQ.
Acquisition of land plots
The process for acquiring land for the purposes of a PPP/concession project set out in the
national legislation is not fully in line with environmental and social requirements of
international financial institutions.
Security
The concept of a security agent is not recognized by the laws in Kazakhstan. Currently, it
appears that the only feasible option for structuring security in PPP/concession projects by a
syndicate of lenders requires one of the lenders to take on the role of a security agent.
Approval process for
concessions
The approval process of a concession concept and tender documentation under the
Concession Law is too complicated and rigid.
EBRD is actively working with all PPP stakeholders to resolve current
legal issues.
30
PPP legislation in Kazakhstan: substantial potential for improvement
Contact Us
31
Our Contacts
32
Ekaterina Miroshnik, Director, Head of Infrastructure Eurasia
E: [email protected] T: +44 7921039930
Svetlana Radchenko, Associate Director, Senior Banker
E: [email protected] T: +44 7843410142
Agris Preimanis, Director, Head of Kazakhstan
E: [email protected] T: +7 7017220690
New Reality – Transformation of Business and Opportunities
Nickolay Demidov
General Manager
IQVIA Russia/CIS
IQVIA
© 2020. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
Evolvement of Central Asian countries
pharmaceutical markets
New reality - Transformation of
business and opportunities
Nickolai Demidov
GM IQVIA Russia&CIS
35
EAEU&CIS region economic growth rate is expected to accelerate in 2019-2024; countries differ significantly in per capita GDP value
Population GDP
3
4
5
6
7
2 3 4 5 6
Fo
recaste
d 4
y C
AG
R [
2019
-2024]
Actual 4y CAGR [2015-2019]
Russia
North West Africa
EAEU w/t RussiaGULF & Middle East
CEE
Turkey
Ukraine
CIS
Size of the bubble refers to GDP value in 2019, USD
Region Population[M 2019]
GDP per capita[K USD, 2019]
Russia 147 29 642
EAEU w/t Russia 37 21 139
Kazakhstan 19 28 849
Belarus 9 20 644
Kyrgyzstan 6 4 056
Armenia 3 11 084
Ukraine 42 9 775
CIS 69 11 267
Uzbekistan 33 9 000
Azerbaijan 10 18 616
Mongolia 3 14 308
Georgia 4 12 227
Moldova 4 7 702
EAEU & CIS macroeconomic landscape
• CIS GDP is expected to grow 7-8% annually in 2019-2024 and exceed regional growth by 3-4% that will drive future outlook of the region
IQVIA power breakfast, Kazakhstan, 30 April 2020
36
2019 Units per capita
EAEU & CIS region
Russia 38
EAEU w/t Russia 32
Ukraine 44
CIS 16
Benchmark regions
CEE region 37
North West Africa 16
GULF & Middle East 20
Turkey 31
CIS region is still behind the region with potential for further expansion in consumption and income level
Key indicators [2019], USD (TRD price) Pharmaceuticals consumption
GDP, PPP, Bn, intern. dollars
GDP per capita, PPP
Pharma market
Government share
RX share
Central East Europe 3 531 31 268 31.0 23% 65%
North West Africa 1 159 12 770 5.0 4% 88%
GULF & Middle East 2 399 43 684 11.3 53% n/a
Turkey 2 347 28 264 8.2 91% 95%
Russia 4 349 29 642 21.1 39% 71%
EAEU w/t Russia 792 21 139 2.7 26% 67%
Ukraine 409 9 775 4.1 12% 55%
CIS 760 11 024 1.9 26% 67%
EAEU & CIS vs. benchmark countries
• Top-5 EAEU & CIS countries (excluding Russia) represent ~76% of total region population: Ukraine (28%, 42 Mln), Uzbekistan (22%, 33 Mln),
Kazakhstan (13%, 19 Mln), Azerbaijan (7%, 10 Mln) and Belarus (6%, 9 Mln)
IQVIA power breakfast, Kazakhstan, 30 April 2020
37
State funding is still low due to economic situation and frequent regulation changes although efforts to increase the state support are implementing
91%
Georgia
61%Russia
27%
65%
39% 61%Kazakhstan
73%
88%
Belarus
Ukraine
70%30%Kyrgyzstan
Moldova
39%
89%
Mongolia
11%Armenia
12%
85%15%Uzbekistan
80%Azerbaijan 20%
23%
35%
Budget
9%
Retail / OOP
77%
KZ
UZ
UA
AZ
Governments
develop programs
to extend the
support
• Compulsory Health Insurance from 2020
• National Complex Anti-Cancer Plan 2018-2022
• Stating HC system development as a
key priority for the state
• Compulsory Health Insurance from 2021
• Healthcare system reform
• Official parallel import
• Compulsory Health Insurance from 2020
RU• Increasing Government budget for
oncology, cardio TAs (NHIF budget
increase), INNs coverage
expansion
Pharma market value split by channel
EAEU & CIS pharmaceutical market
Low level of state funding is a result of unstable
economic environment and budget constraints
IQVIA power breakfast, Kazakhstan, 30 April 2020
CA
CA
CA
38
Market structure: RX and OTC
Spending on Rx varied from 53% to 74% in EAEU & CIS; countries with higher income have much larger value share of OTC market
36% 29% 30%45%
30% 25% 28% 37% 40%27% 34% 33% 37%
26%
64% 71% 70%55%
70% 75% 72% 63% 60%73% 66% 67% 63%
74%
UkraineRussia KAZ GEOTotal
EAEU
& CIS
EAEU w/t
Russia
CIS UZBBLR ARM KRG AZE MOL MNG
OTC RX
14.6 9.8 10.5 28.8 20.6 4.029.6
23%
EAEU w/t
Russia
MNG
26%
Total
EAEU
& CIS
11%
ARMRussia Ukraine
35%
CIS KAZ BLR
15%
KRG UZB AZE GEO MOL
12%
38%
26%
37%
26%30%
20%23%
9%
Government share
11.1 9.0
Comments
Rx and OTC market
structure depends on
income level of population
along with government
coverage of the drugs and
prescription regulations
Pharma market structure [2019, bnUSD]
18.6 12.2 7.7 14.316.1
xx.x GDP2) per capita [k USD]
IQVIA power breakfast, Kazakhstan, 30 April 2020
39
Price dynamics in the EAEU&CIS countries
Many countries within the region are mainly driven by consumption growth while prices are growing in average by 6%
Price dynamics across region 2017-2019 Growth drivers
3Y Volume CAGR
Price per SU 3Y CAGR %
-4
-2
0
2
4
6
8
10
12
14
16
18
-3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
MOL
UKR
UZB
KRG
ARM
BLRKAZ
AZE
GEO
-2%
8%
23%
Armenia
Belarus
11%
Moldova
10%
9%
Uzbekistan
Kazakhstan
Kyrgyzstan
8%
15%
12%
Ukraine
Azerbaijan
10%Georgia
6%
7%
3%
13%
18%
9%8%
3%
2% 8%
Russia
6%1%
-2%
15%
1%
3%
10% 2%
10% 13%
Volume growth Price growth
More than 540 new launches in EAEU & CIS countries (excluding Russia) over last 5Y (~10% of market growth in 2015-2019)1
IQVIA power breakfast, Kazakhstan, 30 April 2020
40
Share of local players
Despite localization push and policies implementation in many countries share of local producers is still low
USD m
Market share by manufacturers presence1) [2019, m USD]
8.7 0.6 1.7 0.1 0.2 0.4 0.01 0.01 -6.3 0.01 0.01 0.03
24% 31%16%
45%
14%
39%
13%
76% 69%84%
55%
94%86%
61%
93% 97% 95% 97%87% 93% 100%
EAEU w/t
Russia
Total EAEU
& CIS
BLR
6%
ARMRussia
3%
KAZUkraine CIS
0%7% 3%
KRG
5%
UZB AZE GEO MNG
7%
MOL
• Highest local producers share in Russia, Ukraine and Belarus (30-45%) mainly due to strong heritage / many local producers presented on the market
over the years
• Benchmark countries: Turkey 41%, CEE average 16%, GULF & Middle East 27%, North West Africa 40%
1
0.05
IQVIA power breakfast, Kazakhstan, 30 April 2020
41
COVID-19 played in favor of markets growth at the beginning of pandemic. Further impact is mainly about negative pressure on the markets
USD m
539,1
UZBEKISTANKAZAKHSTAN
491,2
52,6 57,6
KYRGYZSTAN
331,2288,9
+9,8%
+9,6%
-12,8%
YTD’04’19
YTD’04’20
57,8216,9 214,5 206,9
254,9
KAZAKHSTAN
47,3
UZBEKISTANKYRGYZSTAN
+17,5%
+22,1%
-3,5%
UNITS m
Sales by Countries, Growth (YTD’4’20/ YTD’4’19, Mln.USD, Mln.Units)
As well as at many other markets COVID-19 pandemic led to splashed sales in March, it also had immediate
affect on devaluation of national currencies and markets values had been grown rather slowly or even declining
42
Current new estimation for market growth is more positive for 2020, long term COVID-19 impact is likely to slow down dynamic
IQVIA power breakfast, Kazakhstan, 30 April 2020
Key change drivers
Revised IQVIA market prognosis estimate: +11-15% vs +7,9% pre-COVID
Pharma market changes Impact
Economic recession as impact of COVID-19 outbreak (oil price drop, unemployment increase,
income level decrease, tenge devaluation)
Limitations on F2F visits / promotion to physicians boost as result of COVID-19 lockdowns and
hospitals quarantine
Introduction of obligatory health insurance with increase of patients coverage from 2 mln to 3,5 mln
patients and number of products covered (by 225 products)
Price regulation for all drugs on the market including wholesaler and retail margins
Digital and remote channels (e-commerce, telemedicine, remote promotion) expansion
Supply chain disruption as COVID-19 impact (e.g. API production and supply issues)
Increase in drugs consumption both in Retail and Budget channels in Q1’20 driven by COVID-19
situation
Kazakhstan example
43
Introduction to selected market trends in EAEU & CIS region
Overall EAEU & CIS region remains attractive for pharma companies driven by consumption development, regulatory changes and higher transparency
CHALLENGES AND THREATS KEY MARKET DRIVERS
2
3
1
Government budgets expansion in two directions: selected therapies budget increase (oncology, cardio etc.) and additional budget sources (e.g. compulsory health insurance in Kazakhstan, Azerbaijan, Uzbekistan)
Regulatory changes: ongoing healthcare reform in Ukraine, tender process in Uzbekistan etc.)
Consumption acceleration driven by increasing diagnostic level, patients coverage, income growth and economic recovery, innovative therapies consumption increase
3
4
2
Low penetration of medical services / diagnostic level (low educational level of physicians, diagnostic level for special diseases etc.)
Pricing pressure: tight prices controls in Kazakhstan and Azerbaijan, potential introduction of price control in Ukraine, Uzbekistan, generics substitution)
Local government initiatives / promotional restrictions (e.g. f2f visits restriction in Kazakhstan, prescription controls, official parallel import in Ukraine)
IQVIA power breakfast, Kazakhstan, 30 April 2020
1COVID-19 Pandemic: Overcome the consequences of COVID-19 pandemic which provides challenges for both pharma business and whole economy
Panel Discussion with Austrian healthcare companies
• Arminas Macevicius
Head of Asia-Caucasus Cluster, Takeda GmbH
• Ralph Lugbauer
CEO, Askin GmbH
PANEL
DISCUSSION
Lisa Kronreif, MSc.Die österr. Wirtschaftsdelegierte Stv.AußenwirtschaftsCenter AlmatyT +7 727 22 51 484E [email protected] W wko.at/aussenwirtschaft/kz
THANK YOU!
CONTACT US!
Follow me on…
www.wko.at/aussenwirtschaft/traineeblog
@lisa_kronreif, #careerexport
Lisa-Maria Kronreif, fb.com/exportyourcareer